VMAT2 inhibitors for the treatment of tardive dyskinesia

Tardive dyskinesia (TD) is an often disabling hyperkinetic movement disorder caused by exposure to dopamine receptor blocking agents. Although initially thought to most commonly occur with typical antipsychotics, the incidence is likely similar with atypical antipsychotics and antiemetics such as metoclopramide. Increased prescribing of these agents as well as low rates of remission have contributed to a rising prevalence of TD. Although this condition was described nearly 60  years ago, it is only within the past year that two novel therapeutic agents were FDA approved.
Source: Journal of the Neurological Sciences - Category: Neurology Authors: Tags: Review Article Source Type: research